ArticleImmunologic research2018
IL-2 mediates NK cell proliferation but not hyperactivity.
Article in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Cytokine-induced expandable memory NK cells with significant metabolic, epigenetic remodeling, and persistence properties.Cell death discovery · 2026Article
- DNAM-1 mediates NK-cell activation and host-pathogen interaction via direct binding to fungal cell wall proteases.Communications biology · 2026Article
- Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBVLife (Basel, Switzerland) · 2024Article
- Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.Clinical and experimental medicine · 2023Review
- DHEA Induces Sex-Associated Differential Patterns in Cytokine and Antibody Levels in Mice Infected withInternational journal of molecular sciences · 2023Article
- Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy.Scientific reports · 2023Article
- Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Investigation of Immunostimulatory Effects of Heat-TreatedFood science of animal resources · 2022Article
- The Promises of Natural Killer Cell Therapy in Endometriosis.International journal of molecular sciences · 2022Review
- Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.Molecular cancer · 2022Review
- Mathematical Modeling of Proliferative Immune Response Initiated by Interactions Between Classical Antigen-Presenting Cells Under Joint Antagonistic IL-2 and IL-4 Signaling.Frontiers in molecular biosciences · 2022Article
- IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25eLife · 2021Article
- [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Implications of a 'Third Signal' in NK Cells.Cells · 2021Review
- Notch1 is crucial for decidualization and maintaining the first pregnancy in the mouse†.Biology of reproduction · 2021Article
- Increased Levels of CD107a and Intracellular Cytokines in IL-2 Stimulated PBMCs from Endometriosis Patients.International journal of inflammation · 2021Article
- Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity.Frontiers in immunology · 2021Review
- Functional and metabolic targeting of natural killer cells to solid tumors.Cellular oncology (Dordrecht, Netherlands) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Natural killer cells play a major role in innate immunity against tumor and virus-infected cells. NK cells express activating and inhibitory receptors to regulate their function. It has been established that modulation in the NK cell receptor profile results in altered function of NK cell against target cells. Here, we study the effect of IL-2 stimulation on NK cell inhibitory receptors Ly49A, Ly49C, and activating receptor Ly49D in C57BL/6 mice. It was observed that there was significant increase in expression of Ly49A but no change in expression of Ly49C and Ly49D on IL-2 stimulation. We further noticed that although IL-2 stimulation increased the NK cell population and expression of activation marker NK1.1 but IL-2 stimulation does not cause hyper-responsiveness in NK cells, as there was no increase in MIP-1α and IFN-γ production in IL-2 stimulated NK cells as compared to unstimulated controls. These findings provide a framework to understand the effect of IL-2 stimulation on cognate and non-cognate receptor ligand interactions and suggest stratagies for immunotherapies in conjunction with IL-2 combinatorial therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.